Department of Oncology Radiotherapy, Jiangxi Cancer Hospital, Nanchang, China.
Department of Clinical Medicine Research Center, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China;
Drug Deliv. 2023 Dec;30(1):2161671. doi: 10.1080/10717544.2022.2161671.
Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfully developed for oral AmB administration, currently undergoing phase I clinical trials. Encouragingly, lipid-AmB conjugates with emulsions also exhibit a better bioavailability, which may be another strategy to design oral AmB formulation in clinical practice. Thus, this review mainly focused on the two lipid-based formulations in clinical trials, and discussed the potential perspectives of AmB-lipid conjugation-loaded nanocochleates and emulsions.
两性霉素 B（AmB）被视为治疗危及生命的侵袭性真菌感染的一线药物。由于其口服生物利用度差，AmB 在临床实践中仅限于静脉给药。随着科学的不断进步，目前正在进行 I 期临床试验的两种基于脂质的制剂已成功开发用于口服 AmB 给药。令人鼓舞的是，脂质-AmB 缀合物与乳液也表现出更好的生物利用度，这可能是设计临床实践中口服 AmB 制剂的另一种策略。因此，本综述主要集中在临床试验中的两种基于脂质的制剂，并讨论了两性霉素 B-脂质缀合物载纳米耳蜗和乳液的潜在前景。
